This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / AskBio completes AB-1002 trial enrollment
Tech clinical trial

AskBio completes AB-1002 trial enrollment

Analysis based on 6 articles · First reported Apr 01, 2026 · Last updated Apr 01, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The completion of enrollment for the GenePHIT trial by AskBio, a subsidiary of Bayer, signals significant progress in developing a new gene therapy for heart failure. This could lead to increased investor confidence in Bayer's pharmaceutical pipeline and potentially open up a new market for AB-1002, impacting the biotechnology and pharmaceutical industries positively.

Biotechnology Pharmaceuticals
Event Summary

AskBio, a subsidiary of Bayer, announced the completion of enrollment for its GenePHIT Phase 2 clinical trial of AB-1002, an investigational gene therapy for heart failure with reduced ejection fraction (HFrEF). The trial, which includes 173 participants, aims to assess the safety and efficacy of AB-1002, administered as a single intracoronary infusion. Initial results from the GenePHIT trial are anticipated in the first half of 2027. This milestone is considered a significant step in addressing the global public health challenge of heart failure, which affects an estimated 64 million people worldwide.

Entities Involved
oth
AB-1002
AB-1002 is an investigational gene therapy being developed by AskBio for heart failure. The completion of its Phase 2 clinical trial enrollment is a critical step towards its potential approval and market entry.
Importance 100.0 Sentiment 60.0
oth
GenePHIT
GenePHIT is the Phase 2 clinical trial for AB-1002, which has completed enrollment. Its successful completion and positive results are crucial for the development of AB-1002.
Importance 100.0 Sentiment 60.0
priv
AskBio
AskBio announced the completion of enrollment for its GenePHIT Phase 2 clinical trial of AB-1002, a significant milestone in its heart failure clinical program. This advancement could lead to a new treatment for heart failure, positively impacting AskBio's future prospects.
Importance 90.0 Sentiment 70.0
per
Timothy D. Henry
Timothy D. Henry is the GenePHIT Principal Investigator and Steering Committee Member, providing expert commentary on the significance of the trial's progress for heart failure treatment.
Importance 40.0 Sentiment 50.0
per
Canwen Jiang
Importance 0.0 Sentiment 0.0
stock
Bayer
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.